Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity".
Zydus Lifesciences Limited Press Release Aug 21 2026
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced final approval from the USFDA for Ascorbic Acid Injection, which includes a period of exclusivity for competitive generic therapies. The injection is intended for the treatment of scurvy in patients who cannot take oral medication. The product will be manufactured at Zydus' USFDA-approved facility in Gujarat and marketed in the US by Zydus Pharmaceuticals (USA) Inc.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Zydus Hospitals Sets New Benchmarks in High-Risk Pregnancy and Complex Gynaecological Care
- Zydus Lifesciences Limited Press Release Aug 11 2026
- Zydus Lifesciences Limited Press Release Aug 04 2026
- Zydus Lifesciences Limited Press Release Aug 01 2026
- Zydus Lifesciences Limited Press Release Jul 23 2026
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Aug 31 2026
- Zydus Lifesciences Limited Press Release Sep 26 2026
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences